TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
SciSparc Ltd. ( (SPRC) ) just unveiled an update.
On December 2, 2025, SciSparc Ltd. announced that its subsidiary, NeuroThera Labs Inc., has signed a non-binding term sheet to acquire a 55% stake in an Israeli quantum computing bio data company. This acquisition aims to leverage quantum computing for enhanced clinical analytics, potentially transforming medical research and development. The deal is subject to due diligence and regulatory approvals, and its completion could significantly impact SciSparc’s operations by integrating advanced quantum technologies into its pharmaceutical research.
More about SciSparc Ltd.
SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based pharmaceuticals. Through its majority-owned subsidiary, NeuroThera Labs Inc., SciSparc is engaged in drug development programs targeting central nervous system disorders such as Tourette syndrome, Alzheimer’s disease, and autism spectrum disorder. The company also has a stake in a subsidiary that sells hemp seed oil-based products on Amazon.
Average Trading Volume: 5,321,644
Technical Sentiment Signal: Sell
Current Market Cap: $2.98M
Learn more about SPRC stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “About Three Weeks”: Tesla Stock (NASDAQ:TSLA) Slips as Driverless Robotaxis About to Hit Austin
- “Soulless” Options Put on Notice: Starbucks Stock (NASDAQ:SBUX) Notches Up as Niccol Continues to Plead Third-Place
- “We Anticipate These Pressures Will Persist”: Home Depot Stock (NYSE:HD) Gains Despite Housing Market Troubles